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Abstract
Introduction: Oral mucositis induces severe oral pain in head and neck cancer patients. There is at this point no effective pain
treatment without considerable side effects.
Objective: The aim of this pilot study was to investigate pain reduction in oral cavity and pharynx in patients with head and neck
cancer (HNC) with oral mucositis, the location of anesthetic effect, and duration of pain relief, after a single-dose administration of
a 25 mg bupivacaine lozenge.
Methods: Ten patients with HNC suffering from oral mucositis pain were included. The patients assessed pain in the oral cavity and
pharynx on a visual analogue scale (from 0 to 100 mm) at baseline and up to 3 hours after the lozenge was dissolved. Possible
adverse events were registered.
Results: The baseline pain was 51mm (range: 30–73mm) in the oral cavity and 58mm (range: 35–70mm) in the pharynx.When the
lozengewas dissolved, both oral (227mm; range:23 to252mm;P5 0.0003) and pharynx pain (220mm; range:23 to245mm;
P 5 0.008) were significantly reduced. After 180 minutes, the mean reduction in pain was significant in the oral cavity (218 mm;
range: 28 to 230 mm; P , 0.0001) but not in the pharynx (28 mm; range: 14 to 223 mm; P 5 0.12). No adverse events were
observed.
Conclusion: The results indicate that the bupivacaine lozenge has a clinically significant and long-lasting pain-relieving effect on
pain because of oral mucositis in patients with HNC.
Keywords: Pain management, Bupivacaine lozenge, Local anesthetic, Oral mucositis, Palliative care, Head and neck cancer
1. Introduction
Oral mucositis induces severe oral pain as a serious and very
unpleasant complication primarily due to cancer treatment, but can
also bedue to immunodeficiency causedby infections and systemic
inflammatory diseases. The vast majority of patients undergoing
radiation therapy with or without high-dose chemotherapy for head
and neck cancer (HNC) will develop oral mucositis in degrees
ranging fromminor erythema of the oral mucosa to large debilitating
and painful ulcers.12,17,18,22 The first visible indication of oral
mucositis is erythema, which may appear within the first 2 weeks
after the beginning of radiation therapy. The symptoms may
continue for weeks after the treatment has ended.30
Patients report oral mucositis as one of the worst side effects of
cancer therapy.20 The pain associatedwith oral mucositis makes it
difficult for the patient to eat, speak, or socialize without pain,
resulting inmalnutrition and social withdrawal.10 The loss of normal
oral function leads to a high rate of parenteral nutrition with the use
of gastric feeding tube because of swallowing difficulties and
dysphagia, affecting food and fluid intake.28 Furthermore, oral
mucositis increases the risk of treatment delays, interruptions, or
dose reductions in chemotherapy and radiotherapy.4,27,29
Mild oral pain can be treated with topical viscous lidocaine and
systemic nonsteroidal antiinflammatory drugs (NSAIDs), para-
cetamol (acetaminophen), or gabapentin.5,31 For severe pain,
morphine is used as systemic pain relief,3,35 however, opiates are
not very effective.26 Topical oral formulations with different local
analgesic agents exists and has been examined, however, no
conclusive beneficial effect has been demonstrated on severe
mucositis pain.25,34
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A new lozenge containing 25 mg bupivacaine as a local
oromucosal and pharyngeal anesthetic has been developed and
earlier tested in phase 1 trials with 10 healthy subjects and phase
2A trials with 10 patientswith HNC. In these studies, absorption of
bupivacaine and the risk of aspiration were investigated and no
toxic plasma concentrations or signs of aspirationwere observed,
whereas the results indicated that a bupivacaine lozenge is safe
to use.14,15
The effect of bupivacaine administered as a lozenge has earlier
been tested in 2 other phase2 trials. The 25mg lozengewas tested
for its anesthetic effect in patients undergoing unsedated upper
gastrointestinal endoscopy,24 and a 5 mg bupivacaine lozenge
was examined in patients with burning mouth syndrome,32 both
trials with positive results and no side effects were registered.
Bupivacaine was chosen as the active ingredient in the lozenge
because it is expected to adapt a long duration because of
physiochemical properties.6 The purpose of pain management
with a lozenge is to maintain and enhance patient’s nutritional
status by anesthetizing the oral cavity beforemeals and to improve
the quality of life for the patient by providing sufficient pain relief.
Aim of this pilot study was to investigate pain reduction in oral
cavity and pharynx because of oral mucositis in patients with
HNC. The location of anesthetic effect and duration of pain relief
was examined, after administration of a single-dose 25 mg
bupivacaine lozenge.
2. Materials and methods
2.1. Participants
Patients diagnosed with a HNC undergoing curative (,6 month
duration of disease) radiation therapy were included in this
uncontrolled pilot study. The inclusion criteria for the patients
were a diagnosis with HNC, age more than 18 years, oral pain
from oral mucositis, and the ability to speak and read Danish. The
exclusion criteria were known allergies to bupivacaine or other
local anesthetics of the amide type.
2.2. Ethics
The study was approved by the Danish Health and Medicine
Authority (EudraCT 2010-024648-14), the National Committee
on Health Research Ethics (H-1-2011-003, notification 34449
and 40739), and the Danish Data Protection Agency (J. no. 2011-
41-5711). Furthermore, it was monitored by the Good Clinical
Practice unit at Copenhagen University Hospitals.
2.3. Measurements
The World Health Organization’s grading scale of mucositis was
used for the assessment of oral mucositis based on subjective
and objective symptoms,19 where 0 5 no objective symptoms;
1 5 erythema 6 soreness, no ulcerations; 2 5 erythema and
ulcerations; 3 5 ulceration and distinct erythema, the patient
cannot swallow solid food; and 45 oralmucositis to a degree that
makes normal nutrition impossible.
The patients assessed pain in the oral cavity and the pharynx
on a visual analogue scale (VAS) from 0 (no pain) to 100 mm
(worst possible pain). The mean maximum reduction (pain
alleviation) was calculated by the mean of the differences
between the minimum pain (VAS) measured and the baseline
pain (VAS) (E [painbaseline (VAS) 2 painminimum (VAS)]).
To assess where the anesthetic effect was located, the
patients were asked (yes/no) if they felt anesthetized on the
anterior part of the tongue, back of the tongue, tongue sides, hard
palate, lips, cheeks, and pharynx, but they were not asked about
the duration of the anesthetic effect.
2.4. Study medicine
The study medicine was produced by the Capital Region
Pharmacy, Denmark. The lozenges were manufactured by
direct powder compression and contained bupivacaine 25 mg
as local anesthetic agent, licorice powder as taste masking, and
aspartame as sweetener.
2.5. Study procedure
The patients assessed pain on VAS at baseline before
administration of a 25 mg bupivacaine lozenge (baseline),
immediately after the bupivacaine lozenge was dissolved, and
continuously thereafter for 3 hours (every 15 minutes for 2 hours
and then every 30 minutes for the last hour). Furthermore, the
patients registered where they felt anesthetized in the oral cavity
and pharynx immediately after the lozenge was completely
dissolved. Possible adverse events were registered during the
studies, and the participants were instructed to contact the
clinician if adverse events occurred in the 24 hours after lozenge
administration.
2.6. Statistical analysis
The power calculation was based on a 1-sample t test with
a minimum clinical relevant reduction in pain of 20 mm on the
VAS. We assumed a power of 80%, a significance level of 5%,
and a SDof 20mm for differences between repeatedmeasures of
VAS, which lead to a sample size of 10 patients.
All demographic data are given as median and ranges. The
immediate effect of the lozenge on the pain is reported as the
mean reduction from the VAS score measured at baseline to
the time where the lozenge was dissolved. The change in pain
was analyzed with a paired t test. P-values less than 5% were
considered significant.
3. Results
Ten patients diagnosedwith HNC (,6month duration of disease)
and oral pain from mucositis were included in the study from the
oncology department at the Department of Oncology at
Rigshospitalet, Copenhagen, Denmark, from November 2014
to June 2015. Demographic data and baseline characteristics are
given in Table 1. No adverse reactions were observed in any of
the patients during the study or in the following 24 hours.
The patients were not administrated any pain medication (eg,
paracetamol, NSAIDs, morphine, or local anesthetics) for a mini-
mum of 2 hours before study start. They assessed their pain at
a mean baseline VAS of 51 mm (30–73 mm) in the oral cavity and
58 mm (35–70 mm) in the pharynx, all patients experienced pain in
the oral cavity, and 7 of them also experienced pain in the pharynx
(VAS.0mm). Themedian time for the lozenge to be dissolvedwas
39 minutes (range: 17–60 minutes) and the individual times for the
lozenge to be dissolved are presented inFigure 1 as the timebefore
the dotted line. Figure 1 shows the patients’ individual pain
assessments and the mean assessment from baseline to 3 hours
after the lozenge was dissolved in the oral cavity (Fig. 1A) and the
pharynx (Fig. 1B). There was a significant reduction in pain
assessment in both the oral cavity and pharynx immediately after
the lozenge was completely dissolved. The mean reduction in oral
pain was227mm (range:23 to252mm;P, 0.001) and220mm
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(range:23 to245mm;P50.008) in thepharynx. Fiveof thepatients
had a clinically significant11,13 pain reduction ($30 mm) immediately
after the lozenge was dissolved. Themeanmaximal reduction in oral
pain was 239 mm (range: 221 to 252 mm; P , 0.001), and the
mean maximal reduction in pharynx pain was236 mm (range:213
to253 mm; P, 0.001).
Themean time for maximal pain reduction after the lozenge was
dissolved was 42 minutes (range: 0–90 minutes) in the oral cavity
and 77minutes (range: 45–105minutes) in the pharynx. Therewas
still a significant reduction inmeanpain of218mm (range:28 to2
30mm;P, 0.001) in the oral cavity after 180minutes,whereas the
similar reduction in the pharynx was28mm (range: 4 to223mm;
P 5 0.12), and not significant (Fig. 1A and B).
The lozenges had the most pronounced effect on the anterior
part of the tongue where all patients experienced an anesthetic
effect, followed by the posterior part of the tongue where 80% of
the patients experienced an anesthetic effect (Fig. 2).
4. Discussion
The results of this pilot study indicate that the bupivacaine lozenge,
as a single dose of 25 mg bupivacaine, which is still investigational,
can be used by patients with oral mucositis for pain alleviation with
Table 1
Demographic data and baseline characteristics.
HNC patients (n 5 10)
Sex, male/female 5/5
Age, y, median (range) 62 (42–78)
BMI, kg/m2, median (range) 20.1 (16.6–28.4)
Completed radiation fractions, median (range) 24 (7–33)
Oral mucositis, WHO grade, median (range) 3 (1–4)
Baseline oral pain, VAS mm, mean (range) 51 (30–73)
Baseline pharynx pain, VAS mm, mean (range) 58 (35–70)
BMI, body mass index; HNC, head and neck cancer patients; VAS, visual analogue scale; WHO, World Health
Organization.
Figure 1. Patient assessment of pain in the oral cavity (A) and the pharynx (B) scored on a VAS (ranging from 0 to 100 mm). The gray curve shows the pain
assessment for each patient, the black curves show the mean assessments, and the dotted lines represent the time to dissolve the lozenges completely. These
times are presented on the left side of the dotted line.
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clinical effect in theoral cavity for aminimumof 3 hours. Furthermore,
the patients experienced no side effects. The mean pain reduction
immediately after the lozenge was dissolved was 227 mm in
oral pain and 220 mm in pharynx using a VAS pain score.
The mean maximum pain reduction was239 mm in the oral cavity
and236 mm in the pharynx.
All patients received systemic pain medication per need,
including paracetamol, NSAIDs, and morphine, however, their
meanVASbaseline painwas 51mm in the oral cavity and 58mm in
the pharynx. Although patients were asked not to take any pain
medication 2 hours before study star, the high baseline pain score
indicates insufficient pain treatment for breakthrough pain. The
baseline pain assessments are in linewith similar studies in patients
with HNC and oral mucositis, where baseline pain scores on a VAS
were found to be between 47 and 67 mm.2,8,31 Previous studies
have shown that a minimum baseline VAS score of .30 mm is
necessary to be able to measure pain relief,31 and that a reduction
in pain intensity of minimum213 mm has a clinical significance for
patients with pain.9 No other studies have investigated the effect of
a lozenge with a local anesthetic in patients with HNC. However,
some studies have investigated the effect of different local
anesthetics such as tetracaine, cocaine, and lidocaine. In 1 study,
tetracaine was administered as an oral gel and showed a positive
effect on oralmucositis–relatedpain.1 Theuse of a cocaine solution
has, in a case report, been reported as effective in 2 patients.16
Lidocaine is effective when administered as an oral cream in
a concentration of 1% lidocaine in patients with acute oral mucosal
pain caused by a trauma or an aphthous ulcer and as a lozenge
containing 8 mg lidocaine for treatment of acute pharyngitis.7,36 In
addition, various systemic drugs have led to similar pain
reductions, ie, mouthwashes with the tricyclic antidepressant
doxepin, ketamine, or morphine.8,23,24 All of these drugs exert
systemic action. These studies suggested a positive effect on oral
pain, but ketamine inparticular had severe side effects suchasmild
confusion, hallucinations, nausea, and dizziness.21
Morphine is widely used in the palliative setting, but studies on
morphine and the doxepin mouthwash have concluded that
additional testing is necessary; the authors of the morphine study
stated that more effort must be made for the development of
alternative oral mucositis pain treatments.33 Most of the studies
with different drugs and formulations have had a positive effect on
pain, but none of them are used routinely for oral mucositis
patients. This study indicates that the lozengemay be an effective
alternative to the existing pain management regimen, or as an
add-on therapy. Furthermore, no side effects from the bupiva-
caine lozenge were reported, and the texture and taste were
found to be acceptable (data not shown).
Patient pain scores were significantly reduced in both the oral
cavity and the pharynx after administration of the lozenge.
However, when asked in which areas they could feel the
anesthetic effect, only 5 of the 10 patients reported an anesthetic
effect in the pharynx. This distinction might result from the fact
that the lozenge has more contact with the mucosa in the mouth
than with the mucosa of the pharynx; however, the pain-relieving
effect was still present in the pharynx.
The low number of patients included and the fact that the study
was not placebo-controlled does not allow for definitive conclu-
sions regarding the pain-relieving effect, but the significant
reduction in pain for a long duration indicates that this 25 mg
bupivacaine lozenge could be an option in future pain manage-
ment. When assessing the effect of a local anesthetic drug, it is
difficult to perform a placebo-controlled study because the active
lozenge has an immediate effect in the oral cavity and pharynx as
shown in this study. Our study was a small phase 2A study, with no
control group. This issue will be addressed in an already initiated
larger randomized controlled phase 2 trial with patients diagnosed
with HNC. Oral mucositis can be due to other causes than
radiation, eg, high-dose chemotherapy or infections. The effect of
the bupivacaine lozenge has not been tested in patients with other
causes for oral mucositis, whereas further studies are needed to
elucidate the effect of the bupivacaine lozenge in these conditions.
The patients included in this study may have taken pain
medication with a long duration before the 2 hours before
study start. However, when looking at the baseline VAS
scores, all patients had severe pain although the patients were
under the influence of pain medication taken 2 hours before
study start.
5. Conclusion
The results indicate that the bupivacaine lozenge induces long-
lasting pain alleviation in patients with oral mucositis. This result
makes the bupivacaine lozenge a promising tool in the treatment
of pain in patientswith oral mucositis, a condition currently difficult
to treat. Further testing in a larger patient population is required to
determine whether the lozenge can be sufficient as pain
management without systemic opioids.
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